Extra scan and blood testing with Y90 radioembolization
Part of Cancer, Digestive system clinical trials.
This study looks at how well Y90 “radioembolization” treatment delivers radiation and how much radiation reaches your body. If you can safely get extra PET/CT scans and blood tests around your treatment, you may be invited to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive Y90 radioembolization using SIR-Spheres or TheraSpheres
- You can come back for extra PET/CT scans after treatment
- You can tolerate extra blood tests before, during, and after the procedure
- You can stay at the hospital for the additional PET/CT scan visit
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This trial tests a treatment called yttrium-90 radioembolization (tiny radioactive beads delivered to the liver) for people with liver cancer that has already been treated before. The goal is to see if it can help control the tumor when other treatments haven't been enough.
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors through a tube. It is for people with one or a few small liver tumors that cannot be removed with surgery or destroyed with heat or cold. The goal is to shrink or control the tumors with fewer side effects.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.